16 results on '"KOBER, LARS"'
Search Results
2. Aptamer Proteomics for Biomarker Discovery in Heart Failure With Reduced Ejection Fraction.
- Author
-
Zhang, Luqing, Cunningham, Jonathan W., Claggett, Brian L., Jacob, Jaison, Mendelson, Michael M., Serrano-Fernandez, Pablo, Kaiser, Sergio, Yates, Denise P., Healey, Margaret, Chen, Chien-Wei, Turner, Gordon M., Patel-Murray, Natasha L., Zhao, Faye, Beste, Michael T., Laramie, Jason M., Abraham, William T., Jhund, Pardeep S., Kober, Lars, Packer, Milton, and Rouleau, Jean
- Published
- 2022
- Full Text
- View/download PDF
3. Periodic Repolarization Dynamics Identifies ICD Responders in Nonischemic Cardiomyopathy: A DANISH Substudy.
- Author
-
Boas, Rune, Sappler, Nikolay, von Stulpnagel, Lukas, Klemm, Mathias, Dixen, Ulrik, Thune, Jens Jakob, Pehrson, Steen D, Kober, Lars D, Nielsen, Jens C. D, Videbaek, Lars, Haarbo, Jens D, Korup, Eva, Bruun, Niels Eske D, Brandes, Axel, Eiskjaer, Hans D, Thogersen, Anna M., Philbert, Berit T., Svendsen, Jesper Hastrup D, Tfelt-Hansen, Jacob D, and Bauer, Axel
- Published
- 2022
- Full Text
- View/download PDF
4. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial.
- Author
-
Pfeffer, Marc A., Claggett, Brian, Lewis, Eldrin F., Granger, Christopher B., Kober, Lars, Maggioni, Aldo P., Mann, Douglas L., McMurray, John J.V., Rouleau, Jean-Lucien, Solomon, Scott D., Steg, Philippe Gabriel, Berwanger, Otavio, Cikes, Maja, De Pasquale, Carmine G., Fernandez, Alberto, Filippatos, Gerasimos, Jering, Karola, Landmesser, Ulf, Menon, Venugopal, and Merkely, Bela
- Published
- 2022
- Full Text
- View/download PDF
5. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
- Author
-
Solomon, Scott D., Vaduganathan, Muthiah, L. Claggett, Brian, Packer, Milton, Zile, Michael, Swedberg, Karl, Rouleau, Jean, A. Pfeffer, Marc, Desai, Akshay, H. Lund, Lars, Kober, Lars, Anand, Inder, Sweitzer, Nancy, Linssen, Gerard, Merkely, Bela, Luis Arango, Juan, Vinereanu, Dragos, Chen, Chen-Huan, Senni, Michele, and Sibulo, Antonio
- Published
- 2020
- Full Text
- View/download PDF
6. SERUM LACTATE AND A RELATIVE CHANGE IN LACTATE AS PREDICTORS OF MORTALITY IN PATIENTS WITH CARDIOGENIC SHOCK -- RESULTS FROM THE CARDSHOCK STUDY.
- Author
-
Greve Lindholm, Matias, Hongisto, Mari, Lassus, Johan, Spinar, Jindrich, Parissis, John, Banaszewski, Marek, Silva-Cardoso, Jose, Carubelli, Valentina, Salvatore, diSomma, Sionis, Alessandro, Mebazaa, Alexandre, Veli-Pekka, Harjola, and Kober, Lars
- Published
- 2020
- Full Text
- View/download PDF
7. Return to Work in Out-of-Hospital Cardiac Arrest Survivors: A Nationwide Register-Based Follow-Up Study.
- Author
-
Kragholm, Kristian, Wissenberg, Mads, Mortensen, Rikke Normark, Fonager, Kirsten, Jensen, Svend Eggert, Rajan, Shahzleen, Lippert, Freddy Knudsen, Christensen, Erika Frischknecht, Hansen, Poul Anders, Lang-Jensen, Torsten, Hendriksen, Ole Mazur, Kober, Lars, Gislason, Gunnar, Torp-Pedersen, Christian, and Rasmussen, Bodil Steen
- Published
- 2015
- Full Text
- View/download PDF
8. Incidence and Predictors of End-Stage Renal Disease in Outpatients With Systolic Heart Failure.
- Author
-
Bosselmann, Helle, Gislason, Gunnar, Gustafsson, Finn, Hildebrandt, Per R., Videbaek, Lars, Kober, Lars, Torp-Pedersen, Christian, Tonder, Niels, Rossing, Kasper, Christensen, Stefan, Kamper, Anne-Lise, Heaf, James, and Schou, Morten
- Abstract
Renal dysfunction is an important prognostic factor in heart failure (HF), but whether this dysfunction progresses to end-stage renal disease (ESRD) is unknown. Therefore, we examined incidence and predictors of ESRD in outpatients with HF.Patients with systolic HF were identified in The Danish Heart Failure database and new-onset ESRD from the Danish Registry on Dialysis. Renal function was estimated by The Chronic Kidney Disease Epidemiology Collaboration equation and patients grouped by estimated glomerular filtration rate (eGFR)—group I: ≥60 mL/min per 1.73 m
2 , group II: 30 to 59 mL/min per 1.73 m2 , group III: 15 to 29 mL/min per 1.73 m2 , group IV: <15 mL/min per 1.73 m2 . Cox hazard models for time to ESRD, to death, and the composite end point of ESRD or death were constructed and predictors of ESRD identified. A total of 8204 patients were included in the analyses. Median age was 70 years (Q, 61-77), 28% were women, median left ventricular ejection fraction was 30% (Q, 24-40), and median eGFR was 68 (Q, 51-85) mL/min per 1.73 m2 . Forty-one patients developed ESRD (1.3/1000 patient-years). Baseline eGFR group II (P<0.001), eGFR group III (P<0.001), eGFR group IV (P<0.001), uncontrolled hypertension (P=0.049), need of diuretics, and age <60 years (P=0.016) were associated with time to ESRD.ESRD is rare in outpatients with systolic HF and is mainly observed in patients with an eGFR <30 mL/min per 1.73 m2 . A low eGFR, age <60 years, need of diuretics, and uncontrolled hypertension identify patients with an increased risk for ESRD. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
9. Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials.
- Author
-
Grand, Johannes, Miger, Kristina, Sajadieh, Ahmad D, Kober, Lars D, Torp-Pedersen, Christian D, Ertl, Georg D, Lopez-Sendon, Jose, Pietro Maggioni, Aldo, Teerlink, John R., Sato, Naoki, Gimpelewicz, Claudio, Metra, Marco, Holbro, Thomas, and Nielsen, Olav W. D
- Abstract
Background: Hypotensive events and drops in systolic blood pressure (SBP-drop) are frequent in patients hospitalized with acute heart failure. We investigated whether SBP-drops are associated with outcomes in patients treated with serelaxin. Methods: Patient-level retrospective analyses of 4 prospective trials investigating serelaxin in acute heart failure. Main inclusion criteria were SBP 125 to 180 mm Hg, pulmonary congestion, and elevated NT-proBNP (N-terminal pro-B-type natriuretic peptide). SBP-drops were prospectively defined as SBP<100 mm Hg, or, if SBP remained >100 mm Hg, a drop from baseline of 40 mm Hg from baseline. Outcomes were a short-term composite outcome (worsening heart failure, hospital readmission for heart failure or all-cause mortality through 14 days) and 180-day mortality. Results: Overall, 2559/11 226 (23%) patients had an SBP-drop. SBP-drop, versus no SBP-drop, was associated with a worse outcome: cumulative incidence of 180-day mortality (11% versus 9%, hazard ratio [HR]. 1.21 [95% CI, 1.05-1.39]; P =0.009) and the short-term outcome (11% versus 9%, HR, 1.29 [95% CI, 1.13-1.49]; P <0.001).> P =0.0005) and 1.22 (95% CI, 0.97-1.56; P =0.09), for each component respectively, with a P value for interaction of 0.05. SBP-drops were associated with a worse short-term outcome in the placebo group (HR, 1.46 [95% CI, 1.19-1.79]; P =0.0003), but not in the serelaxin-group (HR, 1.18 [95% CI, 0.97-1.42]; P =0.10); P interaction=0.003. Conclusions: SBP-drops in patients with acute heart failure and normal to high SBP at admission is associated with worse short- and long-term outcomes especially for SBP <100 mm Hg. However, in patients treated with the intravenous vasodilator serelaxin, SBP-drops seemed less harmful. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT02064868, NCT02007720, NCT01870778, NCT00520806. * This study finds an incidence of 23% of in-hospital hypotensive episodes in a clinical cohort of patients admitted with acute heart failure. These episodes are independently associated with adverse outcomes. However, in patients treated with the intravenous vasodilator serelaxin, systolic blood pressure drops seemed to be less harmful. * Hypotensive events in patients with acute heart failure and normal to high systolic blood pressure at admission is an independent risk factor for adverse short- and long-term outcomes. Its occurrence highlights the need for careful monitoring and urgent management. The observations from the reported analysis suggest that blood pressure lowering in patients hospitalized for acute heart failure with baseline systolic blood pressures between 125 and 180 mm Hg may need to be tempered, taking care to avoid lowering systolic blood pressure below 100 mm Hg, particularly in patients with baseline systolic blood pressure <=140 mm Hg. /div> [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial.
- Author
-
Omar, Massar, Jensen, Jesper, Burkhoff, Daniel, Frederiksen, Peter H., Kistorp, Caroline, Videbaek, Lars, Poulsen, Mikael Kjaer, Gustafsson, Finn Di, Kober, Lars Di, Borlaug, Barry A., Schou, Morten, and Moller, Jacob Eifer Di
- Abstract
Background: Stressed blood volume (SBV) is a major determinant of systemic and pulmonary venous pressures which, in turn, determine left and right ventricular fillings and regulates cardiac output via the Frank-Starling mechanism. It is not known whether inhibition of the SGLT2 (sodium-glucose cotransporter-2) favorably affects SBV. We investigated the effect of empagliflozin on estimated SBV in patients with heart failure and reduced ejection fraction compared with placebo. Methods: This was a post hoc analysis of an investigator-initiated, double-blinded, placebo-controlled, randomized trial. Seventy patients were assigned to empagliflozin 10 mg or matching placebo once daily for 12 weeks. Patients underwent right heart catheterization at rest and during exercise at baseline and follow-up. The outcome was change in estimated SBV after 12 weeks of empagliflozin treatment over the full range of exercise, determined using a recently introduced analytical approach based on invasive hemodynamic assessment. Results: Patients with heart failure and reduced ejection fraction, mean age, 57 years and mean ejection fraction 27%, with 47 patients (71%) receiving diuretics were randomized. The effect of empagliflozin on estimated SBV over the full range of exercise loads showed a statistically significant reduction compared with placebo (-198.4 mL [95% CI, -317.4 to -79.3] P =0.001), a 9% decrease. The decrease in estimated SBV by empagliflozin was significantly correlated with the decrease in PCWP (R =-0.33, P <0.0001).> Conclusions: Empagliflozin treatment significantly reduced SBV compared with placebo after 12 weeks of treatment in patients with stable chronic heart failure and reduced ejection fraction during sub maximal exercise. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03198585. * Twelve weeks of treatment with empagliflozin added to contemporary guideline-directed heart failure therapy significantly reduced estimated stressed blood volume compared with placebo over the full range of exercise by 198.4 mL (9%), while reducing estimated total blood volume by only 65.4 mL (1%) from baseline to 12 weeks follow-up. The decrease in estimated stressed blood volume was correlated with decreases of pulmonary capillary wedge pressure but not with estimated total blood volume. The present data suggest that an effect on the distribution of blood volume may partially explain the salutary effects of empagliflozin on pulmonary capillary wedge pressure in heart failure and reduced ejection fraction. * The effect on the distribution of blood volume may partially explain the salutary effects of empagliflozin on pulmonary capillary wedge pressure in heart failure and reduced ejection fraction. * Modulation of sympathetic activity might be one of the mechanisms explaining the decreased estimated stressed blood volume by empagliflozin. * These data may provide new potential insights into the mechanisms by which empagliflozin improves clinical status in heart failure. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Missed Opportunities: Despite Improvement in Use of Cardioprotective Medications Among Patients With Lower-Extremity Peripheral Artery Disease, Underuse Remains.
- Author
-
Subherwal, Sumeet, Patel, Manesh R., Kober, Lars, Peterson, Eric D., Jones, William S., Gislason, Gunnar H., Berger, Jeffrey, Torp-Pedersen, Christian, and Fosbol, Emil L.
- Published
- 2012
- Full Text
- View/download PDF
12. Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.
- Author
-
Thune, Jens J., Signorovitch, James, Kober, Lars, Velazquez, Eric J., McMurray, John J. V., Califf, Robert M., Maggioni, Aldo P., Rouleau, Jean L., Howlett, Jonathan, Zelenkofske, Steven, Pfeffer, Marc A., and Solomon, Scott D.
- Abstract
The influence of blood pressure on outcomes after high-risk myocardial infarction is not well characterized. We studied the relationship between blood pressure and the risk of cardiovascular events in 14 703 patients with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction in the Valsartan in Myocardial Infarction Trial. We assessed the relationship between antecedent hypertension and outcomes and the association between elevated (systolic: >140 mm Hg) or low blood pressure (systolic: <100 mm Hg) in 2 of 3 follow-up visits during the first 6 months and subsequent cardiovascular events over a median 24.7 months of follow-up. Antecedent hypertension independently increased the risk of heart failure (hazard ratio [HR]: 1.19; 95% CI: 1.08 to 1.32), stroke (HR: 1.27; 95% CI: 1.02 to 1.58), cardiovascular death (HR: 1.11; 95% CI: 1.01 to 1.22), and the composite of death, myocardial infarction, heart failure, stroke, or cardiac arrest (HR: 1.13; 95% CI: 1.06 to 1.21). While low blood pressure in the postmyocardial infarction period was associated with increased risk of adverse events, patients with elevated blood pressure (n=1226) were at significantly higher risk of stroke (adjusted HR: 1.64; 95% CI: 1.17 to 2.29) and combined cardiovascular events (adjusted HR: 1.14; 95% CI: 1.00 to 1.31). Six months after a high-risk myocardial infarction, elevated systolic blood pressure, a potentially modifiable risk factor, is associated with an increased risk of subsequent stroke and cardiovascular events. Whether aggressive antihypertensive treatment can reduce this risk remains unknown. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
13. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
- Author
-
Rohde, Luis E., Claggett, Brian L., Wolsk, Emil, Packer, Milton, Zile, Michael, Swedberg, Karl, Rouleau, Jean, Pfeffer, Marc A., Desai, Akshay S., Lund, Lars H., Kober, Lars, Anand, Inder, Merkely, Bela, Senni, Michele, Shi, Victor, Rizkala, Adel, Lefkowitz, Martin, McMurray, John J.V., and Solomon, Scott D.
- Abstract
Supplemental Digital Content is available in the text. Background: The net clinical benefit of cardiac disease-modifying drugs might be influenced by the interaction of different domains of disease burden. We assessed the relative contribution of cardiac, comorbid, and demographic factors in heart failure (HF) and how their interplay might influence HF prognosis and efficacy of sacubitril/valsartan across the spectrum of left ventricular ejection fraction. Methods: We combined data from 2 global trials that evaluated the efficacy of sacubitril/valsartan compared with a renin-angiotensin antagonist in symptomatic HF patients (PARADIGM-HF [Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure; n=8399] and PARAGON-HF [Prospective Comparison of Angiotensin-Converting Enzyme Inhibitor With Angiotensin Receptors Blockers Global Outcomes in Heart Failure With Preserved Ejection Fraction; n=4796]). We decomposed the previously validated Meta-Analysis Global Group in Chronic Heart Failure risk score into cardiac (left ventricular ejection fraction, New York Heart Association class, blood pressure, time since HF diagnosis, HF medications), noncardiac comorbid (body mass index, creatinine, diabetes, chronic obstructive pulmonary disease, smoking), and demographic (age, gender) categories. Based on these domains, an index representing the balance of cardiac to noncardiac comorbid burden was created (cardiac-comorbid index). Clinical outcomes were time to first HF hospitalization or cardiovascular deaths and all-cause mortality. Results: Higher scores of the cardiac domain were observed in PARADIGM-HF (10 [7–13] versus 5 [3–6], P <0.001) and higher scores of the demographic domain in PARAGON-HF (10 [8–13] versus 5 [2–9], P <0.001). In PARADIGM-HF, the contribution of the cardiac domain to clinical outcomes was greater than the noncardiac domain (P <0.001), while in PARAGON-HF the attributable risk of the comorbid and demographic categories predominated. Individual scores from each sub-domain were linearly associated with the risk of clinical outcomes (P <0.001). Beneficial effects of sacubitril/valsartan were observed in patients with preponderance of cardiac over noncardiac comorbid burden (cardiac-comorbid index >5 points), suggesting a significant treatment effect modification (interaction P <0.05 for both outcomes). Conclusions: Domains of disease burden are clinically relevant features that influence the prognosis and treatment of patients with HF. The therapeutic benefits of sacubitril/valsartan vary according to the balance of components of disease burden, across different ranges of left ventricular ejection fraction. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Serum Lactate and A Relative Change in Lactate as Predictors of Mortality in Patients With Cardiogenic Shock - Results from the Cardshock Study.
- Author
-
Lindholm MG, Hongisto M, Lassus J, Spinar J, Parissis J, Banaszewski M, Silva-Cardoso J, Carubelli V, Salvatore D, Sionis A, Mebazaa A, Veli-Pekka H, and Kober L
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Hemodynamics, Humans, Male, Middle Aged, Multivariate Analysis, Proportional Hazards Models, Lactic Acid metabolism, Shock, Cardiogenic metabolism, Shock, Cardiogenic mortality
- Abstract
Introduction: Cardiogenic shock complicating acute myocardial infarction has a very high mortality. Our present study focuses on serial measurement of lactate during admission due to cardiogenic shock and the prognostic effect of lactate and a relative change in lactate in patients after admission and the institution of intensive care treatment., Methods and Results: This is a secondary analysis of the CardShock study. Data on lactate at baseline were available on 217 of 219 patients.In the study population, the median baseline lactate was 2.8 mmol/L (min-max range, 0.5-23.1 mmol/L).At admission, lactate was predictive of 30-day mortality with an adjusted Hazard ratio (HR) of 1.20 mmol/L (95% confidence interval, CI 1.14-1.27). Within the first 24 h of admission, baseline lactate remained predictive of 30-day mortality. Lactate at 6 h had a HR of 1.14 (95% CI 1.06-1.24) and corresponding values at 12 and 24 h had a HR of 1.10 (1.04-1.17), and of HR 1.19 (95% CI 1.07-1.32), respectively. A 50% reduction in lactate within 6 h resulted in a HR of 0.82 (95% CI 0.72-0.94). Corresponding hazard ratios at 12 and 24 h, were 0.87 (95% CI 0.76-0.98) and 0.74 (95% CI 0.60-0.91), respectively., Conclusion: The main findings of the present study are that baseline lactate is a powerful predictor of 30-day mortality, lactate at 6, 12, and 24 h after admission are predictors of 30-day mortality, and a relative change in lactate is a significant predictor of survival within the first 24 h after instituting intensive care treatment adding information beyond the information from baseline values.
- Published
- 2020
- Full Text
- View/download PDF
15. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty.
- Author
-
Thune JJ, Hoefsten DE, Lindholm MG, Mortensen LS, Andersen HR, Nielsen TT, Kober L, and Kelbaek H
- Subjects
- Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multicenter Studies as Topic, Myocardial Infarction drug therapy, Randomized Controlled Trials as Topic, Thrombolytic Therapy adverse effects, Thrombolytic Therapy mortality, Angioplasty, Balloon, Coronary mortality, Patient Admission, Patients, Risk Assessment methods
- Abstract
Background: Randomized trials comparing fibrinolysis with primary angioplasty for acute ST-elevation myocardial infarction have demonstrated a beneficial effect of primary angioplasty on the combined end point of death, reinfarction, and disabling stroke but not on all-cause death. Identifying a patient group with reduced mortality from an invasive strategy would be important for early triage. The Thrombolysis in Myocardial Infarction (TIMI) risk score is a simple validated integer score that makes it possible to identify high-risk patients on admission to hospital. We hypothesized that a high-risk group might have a reduced mortality with an invasive strategy., Methods and Results: We classified 1527 patients from the Danish Multicenter Randomized Study on Fibrinolytic Therapy Versus Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI-2) trial with information for all variables necessary for calculating the TIMI risk score as low risk (TIMI risk score, 0 to 4) or high risk (TIMI risk score > or =5) and investigated the effect of primary angioplasty versus fibrinolysis on mortality and morbidity in the 2 groups. Follow-up was 3 years. We classified 1134 patients as low risk and 393 as high risk. There was a significant interaction between risk status and effect of primary angioplasty (P=0.008). In the low-risk group, there was no difference in mortality (primary angioplasty, 8.0%; fibrinolysis, 5.6%; P=0.11); in the high-risk group, there was a significant reduction in mortality with primary angioplasty (25.3% versus 36.2%; P=0.02)., Conclusions: Risk stratification at admission based on the TIMI risk score identifies a group of high-risk patients who have a significantly reduced mortality with an invasive strategy of primary angioplasty.
- Published
- 2005
- Full Text
- View/download PDF
16. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).
- Author
-
Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, and Fleming T
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Disease Susceptibility, Double-Blind Method, Etanercept, Female, Heart Failure mortality, Hospitalization statistics & numerical data, Humans, Immunoglobulin G administration & dosage, Immunoglobulin G adverse effects, Infections epidemiology, Life Tables, Male, Middle Aged, Receptors, Tumor Necrosis Factor administration & dosage, Survival Analysis, Treatment Failure, Heart Failure drug therapy, Immunoglobulin G therapeutic use, Receptors, Tumor Necrosis Factor therapeutic use, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
Background: Studies in experimental models and preliminary clinical experience suggested a possible therapeutic role for the soluble tumor necrosis factor antagonist etanercept in heart failure., Methods and Results: Patients with New York Heart Association class II to IV chronic heart failure and a left ventricular ejection fraction < or =0.30 were enrolled in 2 clinical trials that differed only in the doses of etanercept used. In RECOVER, patients received placebo (n=373) or subcutaneous etanercept in doses of 25 mg every week (n=375) or 25 mg twice per week (n=375). In RENAISSANCE, patients received placebo (n=309), etanercept 25 mg twice per week (n=308), or etanercept 25 mg 3 times per week (n=308). The primary end point of each individual trial was clinical status at 24 weeks. Analysis of the effect of the 2 higher doses of etanercept on the combined outcome of death or hospitalization due to chronic heart failure from the 2 studies was also planned (RENEWAL). On the basis of prespecified stopping rules, both trials were terminated prematurely owing to lack of benefit. Etanercept had no effect on clinical status in RENAISSANCE (P=0.17) or RECOVER (P=0.34) and had no effect on the death or chronic heart failure hospitalization end point in RENEWAL (etanercept to placebo relative risk=1.1, 95% CI 0.91 to 1.33, P=0.33)., Conclusions: The results of RENEWAL rule out a clinically relevant benefit of etanercept on the rate of death or hospitalization due to chronic heart failure.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.